Filtered By:
Source: British Journal of Haematology

This page shows you your search results in order of date.

Order by Relevance | Date

Total 34 results found since Jan 2013.

Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition
This study investigated the association of nutritional and haematological variables with maximum time‐averaged mean velocity (TAMV) measured by transcranial Doppler (TCD) velocity and the agreement of classification between two protocols. TCD categories included: normal (<170 cm/s), conditional (170–199 cm/s) and abnormal (≥200 cm/s) based on TAMV in distal internal carotid artery (dICA), middle cerebral artery (MCA), internal carotid bifurcation, anterior and posterior cerebral arteries. Of 358 children with sickle cell anaemia (SCA) examined, the mean age (±standard deviation) was 7·4 ± 2·7 years; 13·...
Source: British Journal of Haematology - March 1, 2018 Category: Hematology Authors: Angela E. Rankine ‐Mullings, Nadine Morrison‐Levy, Deanne Soares, Karen Aldred, Lesley King, Susanna Ali, Jennifer M. Knight‐Madden, Margaret Wisdom‐Phipps, Robert J. Adams, Russell E. Ware, Marvin Reid Tags: Research Paper Source Type: research

How I manage red cell transfusions in patients with sickle cell disease
Summary Sickle cell disease is one of the commonest serious inherited diseases in the world, and red cell transfusion is still one of the few effective treatments for acute and chronic complications. Transfusion corrects anaemia and dilutes out the number of red cells able to cause vaso‐occlusion and vascular damage. Urgent red cell transfusions are used to correct acute anaemia, treat acute chest syndrome and patients with acute neurological symptoms. We use elective transfusions preoperatively for moderate risk surgery, and in some pregnant women. There is good evidence for the use of long‐term regular transfusions i...
Source: British Journal of Haematology - January 29, 2018 Category: Hematology Authors: David C. Rees, Susan Robinson, Jo Howard Tags: Annotation Source Type: research

Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease
Summary Stroke risk in children with sickle cell disease (SCD) is currently assessed with routine transcranial Doppler ultrasound (TCD) measurements of blood velocity in the Circle of Willis (CoW). However, there is currently no biomarker with proven prognostic value in adult patients. Four‐dimensional (4D) flow magnetic resonance imaging (MRI) may improve risk profiling based on intracranial haemodynamics. We conducted neurovascular 4D flow MRI and blood sampling in 69 SCD patients [median age 15 years (interquartile range, IQR: 12–50)] and 14 healthy controls [median age 21 years (IQR: 18–43)]. We measured veloci...
Source: British Journal of Haematology - December 21, 2017 Category: Hematology Authors: Lena V áclavů, Zelonna A. V. Baldew, Sanna Gevers, Henri J. M. M. Mutsaerts, Karin Fijnvandraat, Marjon H. Cnossen, Charles B. Majoie, John C. Wood, Ed VanBavel, Bart J. Biemond, Pim Ooij, Aart J. Nederveen Tags: Research Paper Source Type: research

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma
Abstract This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low‐grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28‐day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion ...
Source: British Journal of Haematology - November 28, 2017 Category: Hematology Authors: Ian W. Flinn, Dana S. Thompson, Ralph V. Boccia, Gerald Miletello, Andrew Lipman, Douglas Flora, Daniel Cuevas, Steven W. Papish, Jesus G. Berdeja Tags: Research Paper Source Type: research

How I manage sickle cell patients with high transcranial doppler results
Summary Stroke is one of the most severe complications to affect children with sickle cell anaemia (SCA). Transcranial doppler (TCD) is an accurate and non‐invasive method to determine stroke risk. Randomised controlled trials have demonstrated the efficacy of chronic transfusion therapy in stroke prevention based on risk stratification determined by TCD velocities. This has led to the regular use of TCD monitoring for children with SCA in order to determine stroke risk. Significant resource allocation is necessary to facilitate training, quality assurance and failsafe arrangements for non‐attenders. In a subgroup of p...
Source: British Journal of Haematology - August 2, 2017 Category: Hematology Authors: John Brewin, Banu Kaya, Subarna Chakravorty Tags: Review Source Type: research

Interleukin ‐6 G‐174C polymorphism predicts higher risk of stroke in sickle cell anaemia
British Journal of Haematology, EarlyView.
Source: British Journal of Haematology - May 23, 2017 Category: Hematology Source Type: research

The severity of anaemia depletes cerebrovascular dilatory reserve in children with sickle cell disease: a quantitative magnetic resonance imaging study
Summary Overt ischaemic stroke is one of the most devastating complications in children with sickle cell disease (SCD). The compensatory response to anaemia in SCD includes an increase in cerebral blood flow (CBF) by accessing cerebrovascular dilatory reserve. Exhaustion of dilatory reserve secondary to anaemic stress may lead to cerebral ischaemia. The purpose of this study was to investigate CBF and cerebrovascular reactivity (CVR) using magnetic resonance imaging (MRI) in children with SCD and to correlate these with haematological markers of anaemia. Baseline CBF was measured using arterial spin labelling. Blood‐oxyg...
Source: British Journal of Haematology - November 30, 2016 Category: Hematology Authors: Przemyslaw D. Kosinski, Paula L. Croal, Jackie Leung, Suzan Williams, Isaac Odame, Gregory M. T. Hare, Manohar Shroff, Andrea Kassner Tags: Research Paper Source Type: research

Stroke in sickle cell anaemia is more than stenosis and thrombosis: the role of anaemia and hyperemia in ischaemia
Source: British Journal of Haematology - November 10, 2016 Category: Hematology Authors: Michael M. Dowling, Fenella J. Kirkham Tags: Editorial Comment Source Type: research

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Stephen P. Mulligan, Christopher M. Ward, David Whalley, Sarah N. Hilmer Tags: Editorial Comment Source Type: research

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%)....
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Philip A. Thompson, Vincent L évy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loic Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, F Tags: Short Report Source Type: research

Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia
Summary Silent cerebral infarction (SCI) is the most common neurological abnormality among children with sickle cell anaemia (SCA). The effect of hydroxycarbamide (also termed hydroxyurea) on the development and progression of SCI is unclear. We evaluated brain magnetic resonance imaging/angiography (MRI/MRA) in children with SCA receiving long‐term hydroxycarbamide therapy. Fifty participants (median 9·4 years, range 1·1–17·3) enrolled in the Hydroxyurea Study of Long‐Term Effects (HUSTLE; NCT00305175) underwent brain MRI/MRA and laboratory evaluations before hydroxycarbamide initiation and after 3 and 6 years ...
Source: British Journal of Haematology - September 7, 2016 Category: Hematology Authors: Kerri A. Nottage, Russell E. Ware, Banu Aygun, Matthew Smeltzer, Guolian Kang, Joseph Moen, Winfred C. Wang, Jane S. Hankins, Kathleen J. Helton Tags: Research Paper Source Type: research

Coagulation factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T gene mutations do not play a major role in symptomatic neonatal arterial ischaemic stroke
Source: British Journal of Haematology - August 31, 2016 Category: Hematology Authors: Juan Arnaez, Gemma Arca, Ana Mart ín‐Ancel, Alfredo Garcia‐Alix Tags: Correspondence Source Type: research

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists
Summary Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic range (TTR), using data from a global population of patients with newly diagnosed non‐valvular AF, the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD‐AF). Among 17 168 patients with 1‐year follow‐up data available at the time of the analysis, 8445 received VKA therapy (±antiplatelet therapy) at enrolment,...
Source: British Journal of Haematology - April 11, 2016 Category: Hematology Authors: David A. Fitzmaurice, Gabriele Accetta, Sylvia Haas, Gloria Kayani, Hector Lucas Luciardi, Frank Misselwitz, Karen Pieper, Hugo Cate, Alexander G. G. Turpie, Ajay K. Kakkar, Tags: Research Paper Source Type: research

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD ‐AF and treated with vitamin K antagonists
Summary Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic range (TTR), using data from a global population of patients with newly diagnosed non‐valvular AF, the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD‐AF). Among 17 168 patients with 1‐year follow‐up data available at the time of the analysis, 8445 received VKA therapy (±antiplatelet therapy) at enrolment,...
Source: British Journal of Haematology - April 11, 2016 Category: Hematology Authors: David A. Fitzmaurice, Gabriele Accetta, Sylvia Haas, Gloria Kayani, Hector Lucas Luciardi, Frank Misselwitz, Karen Pieper, Hugo Cate, Alexander G. G. Turpie, Ajay K. Kakkar, Tags: Research Paper Source Type: research